Actualités Ls 2x Salesforc - CRME | Actions London Stock Exchange

Leverage Shares PLC Issuer Call Redemption Confirmation

Leverage Shares PLC 24 April 2023 Leverage Shares plc 24 April 2023 THIS NOTICE IS IMPORTANT AND REQUIRES THE IMMEDIATE ATTENTION OF THE HOLDERS...

Cardiome Pharma Corp. Permitting Automatic Securities Disposition and Purchase Plans

NASDAQ: CRME TSX: COM VANCOUVER, Dec. 21 /PRNewswire-FirstCall/ -- Cardiome Pharma Corp. (NASDAQ: CRMENASDAQ:/NASDAQ:TSX:NASDAQ:COM) today...

Cardiome Announces Investigational Candidate, Vernakalant, Meets Primary Endpoint in European Comparator Study

NASDAQ: CRME TSX: COM VANCOUVER, Dec. 17 /PRNewswire-FirstCall/ -- Cardiome Pharma Corp. (NASDAQ: CRMENASDAQ:/NASDAQ:TSX:NASDAQ:COM) today...

Cardiome Reports Third Quarter Results

NASDAQ: CRME TSX: COM VANCOUVER, Nov. 9 /PRNewswire-FirstCall/ -- Cardiome Pharma Corp. (NASDAQ: CRMENASDAQ:/NASDAQ:TSX:NASDAQ:COM) today...

Cardiome to Release Third Quarter Results

NASDAQ: CRME TSX: COM VANCOUVER, Nov. 6 /PRNewswire-FirstCall/ -- Cardiome Pharma Corp. (NASDAQ: CRMENASDAQ:/NASDAQ:TSX:NASDAQ:COM) today...

Cardiome To Present At Oppenheimer Healthcare Conference

NASDAQ: CRME TSX: COM VANCOUVER, Nov. 2 /PRNewswire-FirstCall/ -- Cardiome Pharma Corp. (NASDAQ: CRMENASDAQ:/NASDAQ:TSX:NASDAQ:COM) today...

Cardiome And Astellas Announce Initiation Of Patient Enrolment In ACT 5 Trial

NASDAQ: CRME TSX: COM VANCOUVER and DEERFIELD, IL, Oct. 28 /PRNewswire-FirstCall/ -- Cardiome Pharma Corp. (NASDAQ:CRME/TSX:NASDAQ:COM) and its...

Cardiome Pharma Corp. Announces Final Results of Tender Offer

NASDAQ: CRME TSX: COM VANCOUVER, Oct. 16 /PRNewswire-FirstCall/ -- Cardiome Pharma Corp. (NASDAQ: CRMENASDAQ:/NASDAQ:TSX:NASDAQ:COM) ("Cardiome...

Cardiome Pharma Corp. Announces Preliminary Results of Tender Offer

NASDAQ: CRME TSX: COM VANCOUVER, Oct. 14 /PRNewswire-FirstCall/ -- Cardiome Pharma Corp. (NASDAQ: CRME/TSX:NASDAQ:COM) ("Cardiome" or the...

Cardiome Pharma Corp. Announces Commencement of US$27.5 Million Tender Offer

NASDAQ: CRME TSX: COM VANCOUVER, Sept. 1 /PRNewswire-FirstCall/ -- Cardiome Pharma Corp. (NASDAQ: CRME/TSX:NASDAQ:COM) ("Cardiome" or the...

Cardiome Announces Upcoming Presentation Of Results Of Phase 2b Clinical Trial Of Vernakalant (Oral) At The European Society Of

NASDAQ: CRME TSX: COM VANCOUVER, Aug. 28 /PRNewswire-FirstCall/ -- Cardiome Pharma Corp. (NASDAQ: CRMENASDAQ:/NASDAQ:TSX:NASDAQ:COM) today...

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Ls 2x Salesforc (CRME)

Votre Hub pour des idées et discussions en direct en temps réel

CRME Actualités

Leverage Shares PLC Issuer Call Redemption Confirmation

Cardiome Pharma Corp. Permitting Automatic Securities Disposition and Purchase Plans

Cardiome Announces Investigational Candidate, Vernakalant, Meets Primary Endpoint in European Comparator Study

Cardiome Reports Third Quarter Results

Cardiome to Release Third Quarter Results

Cardiome To Present At Oppenheimer Healthcare Conference

Cardiome And Astellas Announce Initiation Of Patient Enrolment In ACT 5 Trial

Cardiome Pharma Corp. Announces Final Results of Tender Offer

Cardiome Pharma Corp. Announces Preliminary Results of Tender Offer

Cardiome Pharma Corp. Announces Commencement of US$27.5 Million Tender Offer

Cardiome Announces Upcoming Presentation Of Results Of Phase 2b Clinical Trial Of Vernakalant (Oral) At The European Society Of

Cardiome Pharma Corp. Announces Tender Offer To Purchase Up To US$27.5 Million Of Its Common Shares

Cardiome Reports Second Quarter Results

Additional Clinical Trial to be Conducted for KYNAPID Under FDA Special Protocol Agreement

Cardiome to Hold Conference Call

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Ls 2x Salesforc (CRME) Actualités

Ls 2x Salesforc (CRME)

Votre Hub pour des idées et discussions en direct en temps réel

CRME Actualités

Leverage Shares PLC Issuer Call Redemption Confirmation

Cardiome Pharma Corp. Permitting Automatic Securities Disposition and Purchase Plans

Cardiome Announces Investigational Candidate, Vernakalant, Meets Primary Endpoint in European Comparator Study

Cardiome Reports Third Quarter Results

Cardiome to Release Third Quarter Results

Cardiome To Present At Oppenheimer Healthcare Conference

Cardiome And Astellas Announce Initiation Of Patient Enrolment In ACT 5 Trial

Cardiome Pharma Corp. Announces Final Results of Tender Offer

Cardiome Pharma Corp. Announces Preliminary Results of Tender Offer

Cardiome Pharma Corp. Announces Commencement of US$27.5 Million Tender Offer

Cardiome Announces Upcoming Presentation Of Results Of Phase 2b Clinical Trial Of Vernakalant (Oral) At The European Society Of

Cardiome Pharma Corp. Announces Tender Offer To Purchase Up To US$27.5 Million Of Its Common Shares

Cardiome Reports Second Quarter Results

Additional Clinical Trial to be Conducted for KYNAPID Under FDA Special Protocol Agreement

Cardiome to Hold Conference Call

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application